4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Shin Nippon Biomedical Laboratories, Ltd. (2395) operates in the Diagnostics & Research industry and is headquartered in Kagoshima, Japan with about 1,680 employees. Its market capitalization is roughly JPY 62 billion. In the fiscal year ended 2026-03-31, 2395 reported JPY 32.5B in revenue and JPY 4.6B in net income.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | JPY 32.5B | JPY 32.4B | JPY 26.5B | JPY 25.1B |
| Gross Profit | JPY 16.2B | JPY 17.0B | JPY 14.3B | JPY 13.0B |
| Operating Income (EBIT) | JPY 2.7B | JPY 3.0B | JPY 4.2B | JPY 5.2B |
| Net Income | JPY 4.6B | JPY 4.9B | JPY 5.5B | JPY 6.1B |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (JPY 2.1B) | (JPY 2.1B) | (JPY 2.1B) | (JPY 2.5B) | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | JPY 105.1B | JPY 92.4B | JPY 76.3B | JPY 57.2B | — |
| Total Liabilities | JPY 61.6B | JPY 52.3B | JPY 42.1B | JPY 30.9B | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2395 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms